Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Pamiparib · BGB-290

Small molecule · Inhibitor of poly(ADP-ribose) polymerase 1 (PARP1) · developed by BeiGene

Phase 1/2 Most advanced trial (none active)
2 Registered trials

What is Pamiparib?

Pamiparib is an orally bioavailable inhibitor of the nuclear enzyme poly(ADP-ribose) polymerase (PARP). It binds PARP and blocks PARP-mediated repair of single-strand DNA breaks through the base-excision repair pathway, leading to accumulation of DNA strand breaks and apoptosis. It is being studied in solid tumors and ovarian cancers, including platinum-resistant ovarian cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
BGB-290
Drug type
Small molecule
Targets
poly(ADP-ribose) polymerase 1 (PARP1)
Mechanism
Inhibitor of poly(ADP-ribose) polymerase 1 (PARP1)
Pathways
base-excision repair (BER), DNA single-strand break repair, apoptosis
Therapy area
Oncology
Developer
BeiGene
In trials of
HCM, MYGN
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2
UNII
8375F9S90C

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05494580 Phase 1/2 Ovarian Cancer Completed HCM
NCT03150810 Phase 1 Locally Advanced or Metastatic Solid Tumors Completed MYGN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Fallopian Tube CarcinosarcomaLocally Advanced or Metastatic Solid TumorsOvarian CancerOvarian CarcinomaPlatinum-resistant Ovarian CancerPrimary Peritoneal Cancer

Other drugs acting on PARP1

Sources

Updated Oct 25, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.